MiMedx Group Inc (MDXG) traded on unusually high volume on Feb. 11, as the stock gained 0.93% to close at $2.71. On the day, MiMedx Group Inc saw 2.06 million shares trade hands on 271 trades. Considering that the stock averages only a daily volume of 1.3 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.
Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.
The stock has traded between $16.62 and $0.95 over the last 52-weeks, its 50-day SMA is now $2.24, and its 200-day SMA $4.68. MiMedx Group Inc has a P/B ratio of 2.11. It also has a P/E ratio of 8.6.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from human amniotic membrane and birth tissues and human skin and bone. Its products are primarily targeted toward the wound-care, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. It also sells OrthoFlo, an allograft derived from amniotic fluid. In addition, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Headquartered in Marietta, GA, MiMedx Group Inc has 690 employees and is currently under the leadership of CEO David Coles.
For a complete fundamental analysis analysis of MiMedx Group Inc, check out Equities.com’s Stock Valuation Analysis report for MDXG.
Still paying commissions on stock trades? Equities.com now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by https://www.equities.com/trading
To get more information on MiMedx Group Inc and to follow the company’s latest updates, you can visit the company’s profile page here: MDXG’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer